Fremont biotech to cut workforce by a third after FDA rejects kidney drug

Job cuts will save the company some $17 million in annual cash compensation, but it didn't outline other ways it expects to conserve cash.

Source: bizjournals.com Health Care:Biotechnology headlines - August 3, 2021 Category: Biotechnology Authors: Ron Leuty Source Type: news